We evaluated the biomarkers Tau-C and Tau-A and the neuroinflammation biomarker C1M, quantifying the area under the receiver operating characteristic curve in patients with PD, with the aim of distinguishing PD patients from healthy individuals. This evidence concerns the gene MAPT and Parkinson disease.